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Abstract: 
 
The use of epigenetic modifiers, such as histone deacetylase inhibitors and DNA 
methyltransferase inhibitors, has been explored increasingly as a technique to induce the 
production of additional microbial secondary metabolites. The application of such molecules to 
microbial cultures has been shown to upregulate otherwise suppressed genes, and in several 
cases has led to the production of new molecular structures. In this study, the proteasome 
inhibitor bortezomib was used to induce the production of an additional metabolite from a 
filamentous fungus (Pleosporales). The induced metabolite was previously isolated from a plant, 
but the configuration was not assigned until now; in addition, an analogue was isolated from a 
degraded sample, yielding a new compound. Proteasome inhibitors have not previously been 
used in this application and offer an additional tool for microbial genome mining. 
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Article: 
 
Introduction 
 
Fungal secondary metabolites are produced via several key pathways, including those involving 
polyketide synthases (PKSs), non-ribosomal peptide synthases (NRPSs), hybrid PKS-NRPS 
(HPN), as well as pathways coding for terpenes and indole alkaloids.1 In fungi, these genes are 
often found in clusters, a fact that has implications on the transcription and regulation of 
secondary metabolite pathways. With the recent completion of fungal genome sequences,2–5 it 
has become clear that the number of gene clusters encoding these pathways greatly outnumbers 
the known secondary metabolites for these organisms.6 A study on the sequence of Aspergillus 
niger demonstrated that less than 30% of its PKS-NRPS- and HPN-encoding gene clusters were 
transcriptionally active.7 This transcriptional suppression has led to a variety of studies delving 
into the mechanisms of transcriptional regulation, as well as developing techniques to induce 
these suppressed pathways. 
 
Efforts have been made to manipulate the epigenetic regulation of gene transcription by growing 
fungi in the presence of various small-molecule modifiers. Such research has focused mainly on 
HDAC (histone deacetylase) inhibitors8–14 and DNA methyltransferase (DNMT) inhibitors,11–
17 in order to make more transcriptionally available the genes that these proteins normally help to 
suppress. Treatment of A. alternata and Penicillium expansum with the HDAC inhibitor 
trichostatin A resulted in increased production of numerous secondary metabolites.9 A similar 
study using the HDAC inhibitor suberoylanilidehydroxamic acid (SAHA) to 
treat A.niger resulted in the isolation of a new metabolite, nygerone A, containing a unique 1-
phenylpyridin-4(1H)-one core that previously had not been reported from any natural 
source.10 Treatment of P. citreonigrum with the DNMT inhibitor 5-azacytidine (5-AZA) 
produced ten additional secondary metabolites, including two new compounds.15 New 
compounds have also been isolated from a SAHA-treated culture of Cladosporium 
cladosporioides and a 5-AZA-treated culture of a Diatrype species.12 The effects of SAHA and 
5-AZA on A. niger gene expression were further characterized by using real-time quantitative 
reverse-transcription PCR to analyze the change in expression of PKS, NRPS, and HPN 
pathways when treated with the epigenetic modifiers;11 all but seven of these 55 gene clusters 
showed increased transcriptional rates. 
 
This study examined the capability of bortezomib, a proteasome inhibitor, to induce the 
production of secondary metabolites in a fungus (MSX 63935, order Pleosporales) that had been 
shown previously to biosynthesize a series of resorcylic acid lactones of polyketide 
origin.18 Proteasomes are protein complexes responsible for the degradation of proteins by 
proteolysis. Among the many proteins degraded by the proteasome pathway, several 
transcriptional regulators have been identified,19, 20 implicating proteasomes as a crucial player in 
gene transcription. Growing MSX 63935 in the presence of bortezomib induced the production 
of an additional secondary metabolite. An analogue was also isolated after degradation of the 
original metabolite in solution, yielding a new compound. 
 
Results and Discussion 
 
Preliminary experiments tested the effects of an HDAC inhibitor (SAHA), a DNMT inhibitor (5-
AZA), and a proteasome inhibitor (bortezomib), on the secondary metabolite production of MSX 
63935 in several growth media. Initial experiments with solid media (rice) showed poor results, 
regardless of very high doses of the epigenetic modifiers (as much as 100 mg per flask). Tests 
with liquid media, including Czapek Dox broth and potato dextrose broth (PDB), were more 
promising. Increased production to the expected metabolites as well as a number of additional 
chromatographic peaks was observed in cultures dosed with epigenetic modifiers (Fig. 1). 
Secondary metabolite production was greater in PDB than Czapek Dox (Fig. S1, Supplementary 
Information), so subsequent experiments used PDB as the culture medium. Extractions of media 
without any fungal growth were used to confirm that the chromatographic peaks were due to 
secondary metabolites and not the media (Fig. S2, Supplementary Information). 
 
Figure 1. Comparison of control (A) and dosed (B–D) growths of MSX 63935 grown in potato 
dextrose broth. The culture shown in (B) was grown with 50 µg/mL SAHA, (C) with 100 µg/mL 
5-AZA, and (D) with 50 µg/mL bortezomib. The separation was performed via UPLC-PDA (235 
nm), using a C18 column and a gradient increasing linearly from 10% CH3CN (H2O) at 0.0 min 
to 100% at 4.5 min, held at 100% for an additional 0.5 min. All extracts were solubilized at 0.2 
mg/mL and injected at a volume of 6 µL. 
 
Of the three inhibitors, bortezomib was chosen for further experiments for two reasons. First, the 
number of additional metabolites in preliminary experiments was greater when the fungus was 
grown with bortezomib than with SAHA. Secondly, while secondary metabolite production by 
bortezomib-dosed cultures was similar to that observed with 5-AZA-dosed cultures, bortezomib 
had not been previously studied for this application. 
 
Triplicate growths of the fungus in PDB containing 0, 25, 50, 75, 100, and 125 µg/mL 
bortezomib were extracted and their organic extracts compared via gradient UPLC-PDA-ELSD 
(Fig. S3, Supplementary Information). Relative levels of the resorcylic acid lactones18 and 
several fatty acids varied between replicate growths. In addition to those expected compounds, a 
new peak was evident in the chromatograms of the bortezomib-dosed growths (arrow, Fig. 2). 
Growths containing this peak were combined; the compound was isolated via preparative high 
pressure liquid chromatography (HPLC), and the structure analyzed. 
 
 
 
Figure 2. Comparison of control (A) and dosed (B) growths of MSX 63935, grown in potato 
dextrose broth with 75 µg/mL bortezomib. The arrow indicates a peak that does not appear in 
extracts of control growths. The peaks in (B) after 4.5 minutes were attributed to fatty acids. The 
separation was performed via UPLC-PDA-ELSD, using a C18 column and a gradient increasing 
linearly from 10% CH3CN (H2O) at 0.0 min to 100% at 4.5 min, held at 100% for an additional 
0.5 min. ELSD data are shown on the left and PDA (235 nm) data on the right. 
 
Compound 1 (Fig. 3, Table 1) was obtained as a white powder. Using HRESIMS a molecular ion 
was measured at 307.1165 [M+H]+ (calcd for C16H19O6, 307.1176), indicating a molecular 
formula of C16H18O6 with eight degrees of unsaturation. The 1H NMR spectrum displayed two 
aromatic m-coupled protons at δH 7.20 (H-6) and δH 7.22 (H-8), a singlet at δH 6.28 (H-3), a 
methoxy signal at δH 3.96, and signals for six protons corresponding to the hydroxylated 
aliphatic side chain at δH 4.06 (H-2′), 2.88 and 2.70 (H-1′a/b), 1.56 (H-3′), 1.56 and 1.45 (H-4′), 
and 0.98 (H-5′). The structure of this side chain was assigned based on examination of COSY 
data (Fig. 4). HMBC correlations (Fig. 4) between H-3 and carbons C-2 (δ 167.0) and C-1′ 
(δC 43.3), as well as between the diastereotopic H-1′ protons and the C-2 and C-3 (δC 112.0) 
carbons, determined the C-2/C-1′ bond. Further analysis of the HMBC and HSQC data and a 
search of the literature suggested the chromone skeleton, which accounted for seven degrees of 
unsaturation.21–23 An HMBC correlation between the methoxy singlet and the C-7 carbon 
(δC 165.4) established its connectivity to the aromatic ring. The mass indicated a carboxylic acid 
moiety as the remaining substituent, accounting for the last degree of unsaturation; this was 
corroborated by a correlation between the H-6 proton and the carboxylic acid carbon (δC 171.9). 
A four-bond correlation between the H-3 proton and C-5 (δC 136.8), established the position of 
the carboxylic acid moiety. The absolute configuration was assigned using a modified Mosher’s 
ester analysis (Fig. 5).24 
 
 
 
Figure 3. Compound 1 was isolated from bortezomib-dosed growths of MSX 63935, and 2 was 
isolated from a degraded solution of 1. 
 
 
Figure 4. Key HMBC (→) and COSY (▬) correlations of compound 1. 
 
 
Figure 5. ΔδH values [Δδ(in ppm) = δS – δR] obtained for (R)- and (S)-MTPA esters (1a and 1b, 
respectively) in pyridine-d5. 
 
Table 1. NMR Data (400 MHz, MeOH-d4) of Compounds 1 and 2.  
1 
 
2 
 
position δH, mult. (J in Hz) δC, type HMBCa δH, mult. (J in Hz) δC, type HMBCa 
2 
 
167.0, C 
  
161.8, C 
 
3 6.28, s 112.0, CH 2, 4, 4a, 5, 1′ 6.21, s 107.3, CH 2, 4, 4a, 5, 1′ 
4 
 
179.4, C 
  
177.6, Cc 
 
4a 
 
114.9, C 
  
112.9, C 
 
5 
 
136.8, C 
  
138.5, Cc 
 
6 7.20, d (2.3) 103.3, CH 4a, 8, 5-COOH 7.13, d (2.3) 100.8, CH 4a, 8, 5-COOH 
7 
 
165.4, C 
  
163.4, C 
 
8 7.22, d (2.3) 116.8, CH 4a, 6, 7, 8a 7.20, d (2.3) 114.0, CH 4a, 7, 8a 
8a 
 
160.6, C 
  
157.9, C 
 
1′a 2.88, dd (4.1, 14.7) 043.3, CH2 2, 3, 2′, 3′ 6.33, dd (1.4, 15.6) 121.5, CH 2, 3′ 
1′b 2.70, dd (9.2, 14.7) 2, 3, 2′, 3′ 
    
2′ 4.06, m 070.0, CH 
 
6.98, dt (7.3, 15.6) 141.8, CH 2, 3′, 4′ 
3′ 1.56, mb 040.8, CH2 1′, 2′, 4′, 5′ 2.31, ddt (1.4, 7.3, 7.3) 034.0, CH2 1′, 2′, 4′, 5′ 
4′ 1.56, mb / 1.45, m 020.1, CH2 2′, 3′, 5′ 1.58, sextet (7.3) 020.9, CH2 2′, 3′, 5′ 
5′ 0.98, t (6.9) 014.5, CH3 3′, 4′ 1.00, t (7.3) 012.1, CH3 3′, 4′ 
7-OCH3 3.96, s 057.1, CH3 7 3.95, s 054.9, CH3 7 
5-COOH 
 
171.9, C 
  
171.5, Cc 
 
aHMBC correlations are from the proton(s) listed to the indicated carbons. 
bOverlapping signals 
cThe quaternary 13C signals for C-4, C-5, and 5-COOH were very weak, and their δC values were 
corroborated by HMBC data. 
 
A compound with the same planar structure as 1 was isolated from the plant Stratiotes aloides in 
2009.22Those authors did not assign the absolute configuration, possibly due to paucity of 
material (less than 200 µg).22Due to signal overlap of the DMSO-d6 solvent, the data reported 
here were obtained in MeOH-d4, though 1H and 13C NMR spectra were also acquired in DMSO-
d6. Key differences between NMR signals in DMSO-d6 were noted at positions H-3, H-6, H-8, 
and C-5 (Table S1, Supplementary Information). However, both the NMR data and the UV 
maxima25 at 233 and 291 supported the chromone skeleton, and the structure of the alkyl side 
chain was firmly assigned by 2D NMR. Coupling of the H-6 and H-8 protons (J = 2.3) 
established the meta positions of the aromatic protons, and the strong four-bond H-3 to C-5 
correlation confirmed the position of the carboxylic acid. 
 
During an unsuccessful attempt to crystalize 1, the molecule degraded in solution, yielding 
several analogues, one in quantities sufficient to assign a structure. Compound 2 (Fig. 3), which 
was new, represented the dehydro analogue of 1, which was supported by an 18 amu difference 
in the HRMS data and an increase by one in the index of hydrogen deficiency. COSY data, 
especially a correlation between H-2′ (δH 6.98) and H-3′ (δH 2.31), helped assign the alkene side 
chain. The large vicinal coupling constant between H-2′ and H-3′ (J = 15.1) established 
the trans configuration. 
 
Both 1 and 2 were tested for cytotoxicity against human melanoma and colon cancer cells and 
were found to be inactive (i.e., IC50 values > 20 µM). 
 
To our knowledge, this is the first use of a proteasome inhibitor in epigenetic modification 
studies to induce additional secondary metabolites from microorganisms, and may inspire new 
methods for the up-regulation of silent metabolite genes. 
 
Experimental Section 
 
Culture Methods 
 
Mycosynthetix fungal strain 63935 was isolated in 1992 by Dr. Barry Katz of MYCOsearch 
from leaf litter. The culture was stored on a malt extract slant and was transferred periodically. A 
fresh culture was grown on malt extract agar in a 10 cm diameter Petri plate at 22 °C for 20 d, 
until the cultures were approximately 2.5 cm in diameter. The cultures were cut into small 
squares, which were used to inoculate 250-mL Erlenmeyer flasks containing 50 mL of potato 
dextrose broth (PDB). At the time of inoculation, 0.5 mL aliquots of DMSO-dissolved 
bortezomib was added in triplicate to 15 flasks, resulting in final concentrations in the liquid 
media of 25, 50, 75, 100, and 125 µg/mL bortezomib. Three flasks were treated with 0.5 mL 
DMSO (vehicle control), and three flasks were untreated (negative control). The cultures were 
grown with shaking (100 rpm) at 22 °C for 14 d. 
 
Extraction and Isolation 
 
The cultures were shaken overnight with 60 mL of 1:1 CHCl3:MeOH and filtered the next day. 
To the filtrate was added 90 mL of CHCl3 and 100 mL of deionized H2O to produce a 4:1:5 
mixture of CHCl3:MeOH:H2O (including the 50 mL of H2O from the liquid media). This mixture 
was stirred for 1 h, then transferred to a separatory funnel. The organic portions were dried in 
vacuo, then shaken with a 1:1:2 mixture of CH3CN:MeOH:hexanes. The CH3CN:MeOH layers 
were separated, and all extracts were dried in vacuo, transferred to scintillation vials, then dried 
completely under air. The extracts of the cultures exhibiting the presence of the new metabolite 
(Fig. 2) were combined (90.85 mg) and subjected to preparative C18 HPLC using an isocratic 
40:60 CH3CN:H2O method over 25 min, followed by a 100% CH3CN column wash (10 min). 
Compound 1 eluted at ~14 min (6.32 mg). 
 
Instrumentation 
 
Optical rotation was measured with a Rudolph Autopol III polarimeter; UV spectra were 
obtained using a Varian Cary 3 UV-vis spectrophotometer. NMR experiments were performed 
on a JEOL ECS 400 MHz NMR equipped with a high sensitivity JEOL Royal probe and an 
autosampler. Selected samples were measured using a Bruker Avance-III 600 MHz NMR. 
HRESIMS data were acquired using a Thermo LTQ Orbitrap XL mass spectrometer equipped 
with an electrospray ionization source. UPLC was performed using a Waters Acquity system, 
equipped with a photodiode array detector (PDA) and evaporative light scattering detector 
(ELSD) with data collected and analyzed using Empower software. A Waters BEH C18column 
(1.7 µm; 50 × 2.1 mm) was used with a 0.6 mL/min flow rate. Preparative HPLC was performed 
using a Varian Prostar HPLC system equipped with ProStar 210 pumps and a Prostar 335 PDA, 
with data collected and analyzed using Galaxie Chromatography Workstation software (version 
1.9.3.2). A YMC ODS-A C18 column (5 µm; 250 × 20 mm) was used with a 9.45 mL/min flow 
rate. 
 
(R)-2-(2-hydroxypentyl)-5-carboxy-7-methoxychromone (1). white powder; [α]20D −26 
(c 0.179, MeOH); UV(MeOH) λmax (log ε) 233 (3.01), 291 (2.85); 1H NMR (400 MHz, MeOH-
d4) see Table 1 and Fig. S4; 13C NMR (400 MHz, MeOH-d4) see Table 1 and Fig. S5; 
HRESIMS m/z 307.1165 (calcd for C16H19O6, 307.1176) [M+H]+. 
 
(E)-2-(pent-1-en-1-yl)-5-carboxy-7-methoxychromone (2). white powder; UV(MeOH) 
λmax (log ε) 256 (3.28), 317 (3.31); 1H NMR (400 MHz, MeOH-d4) see Table 1 and Fig. S6; 13C 
NMR (400 MHz, MeOH-d4) see Table 1 and Fig. S7; HRESIMS m/z 289.1069 (calcd for 
C16H17O5, 289.1071) [M+H]+. 
 
Preparation of (R)- and (S)-MTPA ester derivatives of (1) 
 
To 1.00 mg of compound 1, 1000 µL of pyridine-d5 were added; from this, 500 µL were 
transferred to two separate NMR tubes. To initiate the reaction, 10 µL of S-(+)-α-methoxy-α-
(trifluoromethyl)phenylacetyl (MTPA) chloride were added to one NMR tube and shaken. The 
reaction was monitored immediately by 1H NMR at the following time points: 0, 15, and 30 min. 
At 30 min, an additional 10 µL of S-MTPA chloride were added and the tube shaken. The 
reaction was monitored further at 40, 45, and 55 min, at which point it was determined to be 
complete, yielding the mono (R)-MTPA ester derivative (1a) of 1. To the second NMR tube was 
added 20 µL of the (R)-MTPA chloride; the reaction was shaken, then monitored immediately 
by 1H NMR at the following time points: 0, 15, 30, and 40 min. The reaction was found to be 
complete within 40 min, yielding the mono (S)-MTPA ester derivative (1b) of 1. 1H NMR (500 
MHz, pyridine-d5) of 1a: δH0.80 (3H, t, H-5′), 1.28 (2H, m, H-4′), 1.71 (2H, m, H-3′), 3.14 (2H, 
m, H-1′), 5.78 (1H, m, H-2′), 6.62 (1H, s, H-3). The signals from H-6, H-8, and the methoxy 
group were obscured by solvent and reagent peaks. 1H NMR (500 MHz, pyridine-d5) of 1b: 
δH0.87 (3H, t, H-5′), 1.43 (2H, m, H-4′), 1.77 (2H, m, H-3′), 5.77 (1H, m, H-2′), 6.45 (1H, s, H-
3). The signals from H-1′, H-6, H-8, and the methoxy group were obscured by solvent and 
reagent peaks. 
 
Cytotoxicity Assays 
 
Human melanoma cancer cells designated MDA-MB-435 and human colon cancers designated 
HT-29 were purchased from the American Type Culture Collection (Manassas, VA). The cell 
lines were propagated at 37 °C in 5% CO2 in RPMI 1640 medium supplemented with fetal 
bovine serum (10%), penicillin (100 units/mL), and streptomycin (100 µg/mL). Cells in log 
phase growth were harvested by trypsinization followed by two washings to remove all traces of 
enzyme. A total of 5,000 cells were seeded per well of a 96-well clear, flat-bottom plate and 
incubated overnight (37 °C in 5% CO2). Samples dissolved in DMSO were then diluted and 
added to the appropriate wells (concentrations: 20, 4, 0.8, 0.16, and 0.032 µM; total volume: 
100µL; DMSO: 0.5%). The cells were incubated in the presence of test substance for 72 h at 
37°C and evaluated for viability with a commercial absorbance assay (CellTiter 96®AQueousOne 
Solution Cell Proliferation Assay, Promega Corp, Madison, WI) that measured viable cells. 
IC50 values were expressed by µM relative to the solvent (DMSO) control. The positive control 
was vinblastine tested at 1 nM in MDA-MB-435 cells, yielding 16% viable cells or 10nM in HT-
29 cells, which yielded 39% viable cells. The purity of the compounds was established via UPLC 
prior to cytotoxicity testing (Fig. S8, Supplementary Information). 
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Supplementary material may be found at the end of this formatted article. 
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Table S1. NMR data (400 MHz, DMSO-d6) of compound 1. 
 
Figure S1. Comparison of control (A) and dosed (B-D) growths of MSX 63935 grown in potato dextrose broth 
(left) and Czapek Dox broth (right). 
 
Figure S2. Chromatograms of extracted PDB. 
 
Figure S3. Comparison of bortezomib-dosed growths of MSX 63935 including negative control (A), matrix 
control (B; 0.5 mL DMSO only), 25 (C), 50 (D), 75 (E), 100 (F), and 125 (G) µg/mL bortezomib. 
 
Figure S4. 1H NMR spectrum 1 [400 MHz, MeOH-d4]. 
 
Figure S5. 13C NMR spectrum of 1 [400 MHz, MeOH-d4]. 
 
Figure S6. 1H NMR spectrum of 2 [400 MHz, MeOH-d4]. 
 
Figure S7. 13C NMR spectrum of 2 [600 MHz, MeOH-d4]. 
 
Figure S8. UPLC-PDA (235 nm detection) chromatograms of compounds 1 (top) and 2 (bottom) demonstrating purity. 
 
  
 
Table S1. NMR data (400 MHz, DMSO-d6) of compound 1. The experimental values were measured directly, as were the 
1H NMR literature values (500 MHz, DMSO-d6). The 13C NMR values reported in the literature were derived through 
HMBC and HSQC experiments.  
 Experimental Values  Literature Valuesa 
position δC δH, mult. (J in Hz)  δC δH, mult. (J in Hz) 
5' 13.9 0.86, t (7.1)  14.7 0.86, t (6.9) 
4' 18.2 1.41, 1.32, m  18.9 1.41, 1.32, m 
3' obscured (DMSO) 1.41, m  39.8 1.41, m 
1' 41.7 2.55, dd (8.7, 14.2) 
2.70, dd (4.6, 14.2) 
 42.1 2.55, dd (8.1, 14.5)  
2.66, dd (4.6, 14.3) 
O-Me 56.1 3.87, s  56.2 3.82, s 
2' 67.4 3.88, m  68.0 3.87, m 
6 100.6 6.84, d (2.3)  98.2 6.50, d (2.4) 
3 110.7 6.09, s  110.3 5.98, s 
4a 111.8   111.5  
8 113.1 7.07, d (2.3)  113.4 6.78, d (2.4) 
5 not observed   147.1  
8a 157.8   158.8  
7 162.7   163.5  
2 166.7   166.4  
COOH 169.2   172.6  
4 175.4   177.2  
aConrad, J., et al.; J. Nat. Prod. 2009, 72, 835-840. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Comparison of control (A) and dosed (B-D) growths of MSX 63935 grown in potato dextrose broth 
(left) and Czapek Dox broth (right). Cultures shown in (B) were grown with 50 µg/mL SAHA, (C) with 100 
µg/mL 5-AZA, and (D) with 50 µg/mL bortezomib. The separation was performed via UPLC-PDA (235 nm), 
using a C18 column and a gradient increasing linearly from 10% CH3CN (H2O) at 0.0 min to 100% at 4.5 min, 
held at 100% for an additional 0.5 min.  
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Figure S2. Chromatograms of extracted PDB. The medium (without fungal inoculation) was prepared as 
described in the text and extracted in a manner identical to other samples. The separation was performed via 
UPLC-PDA-ELSD, using a C18 column and a gradient increasing linearly from 10% CH3CN (H2O) at 0.0 min 
to 100% at 4.5 min, held at 100% for an additional 0.5 min. ELSD data are shown on the left and PDA (235 
nm) data on the right.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Comparison of bortezomib-dosed growths of MSX 63935 including negative control (A), matrix 
control (B; 0.5 mL DMSO only), 25 (C), 50 (D), 75 (E), 100 (F), and 125 (G) µg/mL bortezomib. The 
separation was performed via UPLC-PDA-ELSD, using a C18 column and a gradient increasing linearly from 
10% CH3CN (H2O) at 0.0 min to 100% at 4.5 min, held at 100% for an additional 0.5 min. ELSD data are 
shown on the left and PDA (235 nm) data on the right.
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Figure S4. 1H NMR spectrum 1 [400 MHz, MeOH-d4]. 
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Figure S5. 13C NMR spectrum of 1 [400 MHz, MeOH-d4]. 
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Figure S6. 1H NMR spectrum of 2 [400 MHz, MeOH-d4]. 
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Figure S7. 13C NMR spectrum of 2 [600 MHz, MeOH-d4].
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Figure S8. UPLC-PDA (235 nm detection) chromatograms of compounds 1 (top) and 2 (bottom) demonstrating purity. 
The purity of compound 1 is >99%, and the purity of compound 2 is >91%. The separation was performed using a C18 
column and a gradient increasing linearly from 10% CH3CN (H2O) at 0.0 min to 100% at 4.5 min, held at 100% 
for an additional 0.5 min.  
 
 
 
 
